Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions

Inclusion Criteria

• •1. Clinical failure of small-bore chest tube with persistent pleural effusion
• •2. 18 years of age or older
• •3. Eastern Cooperative Oncology Group (ECOG) performance status score 0-2.
• •4. Life expectancy ≥ 6 weeks
• •5. Absolute neutrophil count \> 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 8.0 g/dL
• •6. Serum creatinine ≤2.0 times the upper limit of the normal range, total bilirubin ≤ 2.5 mg/dL, AST/ALT ≤ 5 times the upper limit of normal range
• •7. At least 2 days from administration of chemotherapy
• •8. At least 7 days from prior major surgery
• •9. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 30 days following the last dose of study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial.
• •10. Patient judged to be 'medically stable' by primary investigator.